Genmab A-S

Genmab A-S

Yahoo Finance • 3 days ago

Genmab AS (GMAB) (Q3 2026) Earnings Call Highlights: Revenue Jumps 22% as Epkinly and Pipeline ...

This article first appeared on GuruFocus. Total Revenue: Up 22% year-over-year in the first nine months of 2026, with growth across the portfolio. Adjusted Operating Profit: Grew 9% year-over-year. Darzalex Revenue: Increased 19% year-ove... Full story

Yahoo Finance • 4 days ago

Genmab nine-month revenue rises 22% as late-stage pipeline delivers

Investing.com -- Genmab reported a 22% rise in revenue for the first nine months of 2026 on Thursday, driven by higher royalties from Darzalex and Kesimpta and stronger sales of its cancer drug Epkinly. The Danish biotech maintained its fu... Full story

Yahoo Finance • 11 days ago

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Genmab has seen a sharp rerating on the back of recent oncology trial successes, which puts a fresh spotlight on whether the current share price lines up with the cash flows its pipeline may ultimately produce. With the stock now reflectin... Full story

Yahoo Finance • 12 days ago

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says. Continue Reading... Full story

Yahoo Finance • 14 days ago

Genmab shares jump 13% on colorectal cancer drug trial results

Investing.com -- Genmab shares jumped as much as 13% on Monday after the Danish biotech said its experimental drug petosemtamab, combined with chemotherapy, shrank tumours in 75% of previously untreated patients with advanced colorectal ca... Full story

Yahoo Finance • 15 days ago

Genmab, Incyte team up to develop experimental colorectal cancer treatment

[Incyte headquarters in Wilmington, Delaware, USA] JHVEPhoto/iStock Editorial via Getty Images Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) and Incyte (INCY [https://seekingalpha.com/symbol/INCY]) announced a clinical trial collab... Full story

Yahoo Finance • 16 days ago

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?

Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte... Full story

Yahoo Finance • 16 days ago

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--(BUSINESS WIRE)--Ge... Full story

Yahoo Finance • 16 days ago

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--(BUSINESS WIRE)--In... Full story

Yahoo Finance • 17 days ago

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator's choice chemotherapy Results demons... Full story

Yahoo Finance • 25 days ago

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progr... Full story

Yahoo Finance • 26 days ago

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity InsiderNews Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United Sta... Full story

Yahoo Finance • 27 days ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Genmab A/S Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN,... Full story

Yahoo Finance • last month

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab A/S Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of Directors on... Full story

Yahoo Finance • last month

Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?

Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large... Full story

Yahoo Finance • last month

AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%

AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone,... Full story

Yahoo Finance • last month

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?

Genmab A/S Sponsored ADR (GMAB) shares rallied 10.7% in the last trading session to close at $38.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to th... Full story

Yahoo Finance • last month

AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender

The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. Continue Reading... Full story

Yahoo Finance • last month

Genmab stock surges 11% on positive cancer drug trial data

Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymph... Full story

Yahoo Finance • last month

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B... Full story